There’s power in OPTIONS: Recent developments from the project that is optimizing HIV prevention technology introduction on schedule
“We know that life-changing HIV prevention solutions are available, but it’s critical to think strategically about how an innovation like PrEP is meaningful to our priority users. By understanding who our user is, what is important to them, and how PrEP can be positioned as useful and beneficial, we can help create an enabling environment for PrEP uptake.” - Briana Ferrigno, McCann Health
Oral pre-exposure prophylaxis (PrEP) is a new HIV prevention method that offers more than 90 percent protection when taken correctly. The OPTIONS Consortium, in collaboration with the South African National Department of Health, created five short, powerful videos that encourage PrEP as an acceptable HIV prevention method for adolescent girls and young women.
Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?
Significant resources have created strong ‘test and treat’ programs globally. What about those who test HIV negative? How can we strengthen linkage of HIV-negative individuals to prevention programs in ways that work for them? In our recently completed Test-And-Prevent Analysis, the OPTIONS Consortium identifies practices for linking individuals from HIV testing to HIV prevention. This work aims to identify interventions that are effective, the enabling conditions that support linkage, and remaining questions.
BACKGROUND: Mother-to-child transmission of HIV-1 occurs in a minority of HIV-infected mother-infant pairs, even without any interventions. The mechanisms that protect the majority of HIV-exposed infants from infection are unclear. T regulatory cells (Treg) have important immunomodulatory functions, but their role in the fetus as well as in mother-to-child transmission of HIV is under-studied.
The ring introduction matrix is an early-stage implementation tool intended to help policymakers and implementers consider the introduction of the dapivirine ring alongside oral PrEP.
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. CROI 2019 will be held from March 4 to March 7, 2019, at the Washington State Convention Center in Seattle, Washington.